In Europe, multiple myeloma (MM) treatment is centered on the use of three major agents—Janssen’s Velcade (bortezomib), Celgene’s Revlimid (lenalidomide), and Celgene’s Thalidomide (thalidomide)—while the treatment for non-Hodgkin’s lymphoma (NHL) has Roche’s MabThera (rituximab) as a central player. All of these drugs have demonstrated clear improvements in clinical practice and have achieved significant commercial success within their indications. Multiple emerging agents spanning several different dug classes are in development for MM and NHL. Although many of these emerging therapies appear clinically promising, they face considerable competition from currently available therapies. The presence of several promising agents in development, coupled with dynamic markets, make the MM and NHL indications very exciting from a commercial, as well as a clinical point of view.
Decision Resources Group’s European Physician & Payer Forum report “The Impact of EU5 Payer Policy on Prescribing in Non-Hodgkin’s Lymphoma and Multiple Myeloma” explores reimbursement and additional payer policies that influence prescribing trends for approved targeted agents in MM and NHL. The report assesses levers and barriers that will promote or restrict market access for premium-priced novel agents across the cost-constrained EU5 (France, Germany, Italy, Spain, and the United Kingdom). It draws on insights from 251 surveyed hematological oncologists in the EU5 and from interviews with 15 European payers, all of whom have influence at a national or regional level. Interviewed payers include the following:
- France: hospital pharmacy directors, members of the local formulary committee, and advisors to the Haute Autorité de Santé (HAS; National Health Authority) from northern and southeastern France; hospital pharmacy director and member of the local formulary committee from northern France.
- Germany: ex-Krankenkassen (health insurance funds) member; GBA (Joint Federal Committee of Physicians, Dentists, Hospitals, and Health Insurance Funds) member; member of national boards and ex-GBA member.
- Italy: advisor to the Agenzia Italiana del Farmaco (Italian Medicines Agency) and member of the Prontuario Terapeutico Ospedaliero Regionale (PTO/PTOR; [regional] hospital pharmaceutical formulary) committee in southern Italy; AIFA member from northern Italy; PTO/PTOR member from central Italy.
- Spain: hospital/regional formulary committee members from central, eastern, and southwestern Spain.
- United Kingdom: Clinical commissioning group (CCG) advisor and formulary committee member; CCG advisor and ex-CCG commissioner; CCG advisor and ex-advisor to the National Institute for Health and Care Excellence (NICE).